Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
Condition: DCIS Intervention: Sponsor: Ontario Clinical Oncology Group (OCOG) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2021 Category: Research Source Type: clinical trials
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial
AbstractObjectives1. To assess the efficacy of Mesenchymal Stromal Cells (MSC) versus a control arm as described in the primary endpoint.2. To evaluate the effects of MSC on the secondary efficacy endpoints.3. To evaluate the safety and tolerability profiles of MSC.4. To study soluble and cellular biomarkers that might be involved in the course of the disease and the response to the investigational product.Trial designA double-blind, randomized, controlled, trial to evaluate the efficacy and safety of MSC intravenous administration in patients with COVID-induced Acute Respiratory Distress Syndrome (ARDS) compared to a cont...
Source: Trials - January 6, 2021 Category: Research Source Type: clinical trials
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
Conditions: Ductal Carcinoma in Situ; Extensive Disease; Mastectomy Interventions: Drug: Tamoxifen 20 mg; Drug: Anastrozole 1Mg Tab Sponsor: Institut Cancerologie de l'Ouest Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2020 Category: Research Source Type: clinical trials
